<prompt> Main MOA brimonidine in glaucoma -Decreased aqueous secretionIncreased trabecular outflowIncreased uveoscleral outflowReduce vitreous volume  <response>: Brimonidine 0.2 : 2 timesday. It is a selective alpha-2-adrenergic agonist and lowers IOP by decreasing aqueous production. Because of increased allergic reactions and tachyphylaxis rates it is not considered the drug of first choice in POAG. It is used as second drug of choice and also for combination therapy with other drugs. Ref.AK Khurana 4th edition page no 223 